{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"mogamulizumab"},{"type":"USBrandName","name":"Poteligeo"},{"type":"CodeName","name":"KW-0761"},{"type":"CASRegistryName","name":"1159266-37-1"},{"type":"Synonym","name":"immunoglobulin G1, anti-(CC chemokine receptor CCR4) (human-mouse monoclonal KW-0761 heavy chain), disulfide with human-mouse monoclonal KW-0761 kappa-chain, dimer"},{"type":"CodeName","name":"KM8761"}],"definition":{"html":"A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.","text":"A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/mogamulizumabkpkc","text":"Mogamulizumab-kpkc"},"nciConceptId":"C62510","nciConceptName":"Mogamulizumab","termId":500479,"name":"mogamulizumab-kpkc","firstLetter":"m","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"mogamulizumab"}],"links":null}